金龙胶囊改善恶性肿瘤化疗患者高凝状态的临床分析

Clinical Analysis on Hypercoagulable State of Malignant Tumor Improved by Chemotherapy Combined with Kinglong Capsules

目的:观察金龙胶囊对恶性肿瘤化疗患者高凝状态的影响。方法:将106例恶性肿瘤合并高凝状态患者随机分为观察组及对照组,观察组53例在化疗的基础上同时服用金龙胶囊,每次4粒(1.0 g),一日3次,至下周期化疗开始;对照组53例单纯采用化疗。两组患者每周期化疗前及下周期化疗前检测PLT、Fib、PT、APTT、D-D;两组患者每完成2个周期化疗后进行疗效评价,每周期化疗后评价化疗不良反应。结果:观察组治疗后PT、APTT较对照组治疗后显著延长(P<0.05),PLT、Fib、D-D较对照组治疗后明显降低(P<0.05);观察组和对照组近期疗效差异无统计学意义(P=0.073);观察组Ⅲ～Ⅳ度中性粒细胞减少发生率明显低于对照组(P=0.042)。结论:恶性肿瘤患者化疗同时服用金龙胶囊可延长患者PT、APTT,降低PLT、Fib、D-D水平,从而改善化疗患者的高凝状态。

Objective：This study aims to investigate the effect of Kinglong capsules in malignant tumor patients with hypercoagulable state.Methods： A total of 106 malignant tumor patients with hypercoagulable state were divided into the observation （G1） and control groups （G2）. In G 1, 53 patients started taking the Kinglong capsules （1.0 g each time, 3 times a day） after their first chemotherapy cycle, until the beginning of next chemotherapy cycle. In G 2, the other 53 patients took chemotherapy only. The value of PLT（platelet）, Fib（Fibrinogen）, PT（prothrombin time）, APTT（activated partial thrombopoastin time）, and D-D（D-dimer） for each patient was detected before the initial and the next cycle of chemotherapy. The value of PLT, Fib, PT, APTT, and D-D in the two groups was analyzed using statistical methods. The efficacy was evaluated after two cycles of chemotherapy; adverse reactions were evaluated after each cycle. Result： The time of PT and APTT was prolonged （P=0.021） significantly, and the value of PLT, Fib, and D-D decreased （ P=0.043） significantly after treatment with Kinglong capsules. The short-term therapeutic efficacy was not statistically significant （ P=0.073） between the two groups. Moreover, the Ⅲ–Ⅳdegree of neutropenia was significantly lower in the observation group than the control group （P=0.042）. Conclusion： The results of chemotherapy combined with Kinglong capsules can prolong the PT and APTT time and reduce the value of PLT, Fib, and D-D significantly, thereby improving the hypercoagulable state in malignant tumor patients.